SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era (SCOPE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00187512 |
Recruitment Status
:
Recruiting
First Posted
: September 16, 2005
Last Update Posted
: March 29, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV Infections |
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. Samples from SCOPE will be used to examine:
- Virologic, immunologic, and host factors involved in the natural control of HIV-1 infection (long term non-progression and/or virologic control of HIV-1 without antiretroviral therapy)
- Virologic and immune correlates associated with disease progression
- Evolution of antiretroviral drug resistance
- Factors associated with transmission or acquisition of HIV infection
Enrolled subjects are seen at San Francisco General Hospital every four months for a detailed interview, saliva collection, and blood draw. Baseline visits take approximately one hour, follow up visits take approximately 20-40 minutes. No personal identifiers are used for specimen bank samples.
Study Type : | Observational |
Estimated Enrollment : | 2500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era |
Study Start Date : | March 2000 |
Estimated Primary Completion Date : | March 2019 |
Estimated Study Completion Date : | December 2020 |

- The general theme of this core is to investigate the relationship between the virologic response to antiretroviral therapy and clinical outcome. [ Time Frame: Ongoing ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:
- Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
- Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.
- Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.
- Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.
Exclusion Criteria:
- Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
- Active treatment for cancer
- Active treatment for hepatitis C requiring interferon based therapy
- Immunosuppressive therapy taken within the last 4 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00187512
Contact: Rebecca Hoh, M.S., R.D. | 415-476-4082 ext 139 | Rebecca.Hoh@ucsf.edu | |
Contact: Montha Pao | 415-476-4082 ext 140 | Montha.Pao@ucsf.edu |
United States, California | |
San Francisco General Hospital | Recruiting |
San Francisco, California, United States, 94110 | |
Contact: Rebecca Hoh, M.S. 415-476-4082 ext 139 Rebecca.Hoh@ucsf.edu | |
Contact: Montha Pao 415-476-4082 ext 140 Montha.Pao@ucsf.edu | |
Principal Investigator: Steven G. Deeks, M.D. |
Principal Investigator: | Steven G. Deeks, M.D. | University of California, San Francisco |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00187512 History of Changes |
Other Study ID Numbers: |
10-01330 |
First Posted: | September 16, 2005 Key Record Dates |
Last Update Posted: | March 29, 2017 |
Last Verified: | March 2017 |
Keywords provided by University of California, San Francisco:
HIV Antiretroviral Agents Drug Resistance, Multiple Long Term Non Progression Long Term Non Progressor |
Elite Suppression Elite Suppressor Natural History Observational |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Protease Inhibitors HIV Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |